Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Improving the Care of Incontinence-Associated Dermatitis (IAD) Using a Beta-Glucan Cream
NCT07524439Recruiting
- Sponsor
- University of Alberta
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of Soothing Beta Cream in incontinence-associated dermatitis (IAD) (2 arms), sponsored by University of Alberta. Primary endpoint: Ghent Global IAD Monitoring Tool severity score at 2 weeks. Started May 2026; status: recruiting.
02
Drugs
Soothing Beta Cream
03
Conditions
incontinence-associated dermatitis (IAD)
Beyond the preview
Go deeper on NCT07524439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07524439.